1 Profitable Stock with Impressive Fundamentals and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. Keeping that in mind, here is one profitable company that leverages its financial strength to beat the competition and two that may struggle to keep up.
Two Stocks to Sell:
Lattice Semiconductor (LSCC)
Trailing 12-Month GAAP Operating Margin: 5.3%
A global leader in its category, Lattice Semiconductor (NASDAQ:LSCC) is a semiconductor designer specializing in customer-programmable chips that enhance CPU performance for intensive tasks such as machine learning.
Why Does LSCC Worry Us?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 9% annually over the last two years
- Efficiency has decreased over the last five years as its operating margin fell by 16.2 percentage points
- Free cash flow margin dropped by 4.7 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Lattice Semiconductor is trading at $125.00 per share, or 66x forward P/E. Check out our free in-depth research report to learn more about why LSCC doesn’t pass our bar.
Amphastar Pharmaceuticals (AMPH)
Trailing 12-Month GAAP Operating Margin: 19.4%
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Is AMPH Not Exciting?
- 3.2% annual revenue growth over the last two years was slower than its healthcare peers
- Revenue base of $720.5 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 10.9 percentage points
At $18.92 per share, Amphastar Pharmaceuticals trades at 6.8x forward P/E. To fully understand why you should be careful with AMPH, check out our full research report (it’s free).
One Stock to Buy:
Remitly (RELY)
Trailing 12-Month GAAP Operating Margin: 6.9%
With Amazon founder Jeff Bezos as an early investor, Remitly (NASDAQ:RELY) is an online platform that enables consumers to safely and quickly send money globally.
Why Do We Love RELY?
- Active Customers are rising, meaning the company can increase revenue without incurring additional customer acquisition costs if it can cross-sell additional products and features
- Additional sales over the last three years increased its profitability as the 247% annual growth in its earnings per share outpaced its revenue
- Free cash flow margin expanded by 35.2 percentage points over the last few years, providing additional flexibility for investments and share buybacks/dividends
Remitly’s stock price of $23.39 implies a valuation ratio of 10.8x forward EV/EBITDA. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.